Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 11Phase 1 4Phase 1/2 3Phase 4 1

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × ofatumumab × Clear all
NCT01217749 2015-06-25

PCYC-1109-CA

Pharmacyclics LLC.

Phase 1/2 Completed
71 enrolled 10 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00092274 2015-04-21

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

GlaxoSmithKline

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00093314 2015-04-21

HuMax-CD20 in Chronic Lymphocytic Leukemia

GlaxoSmithKline

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡